Bei Liu

Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome

Jun Yu Li, Liangjing Lu, Mi Zhou, 2022, Biomedicine & Pharmacotherapy.

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer

Liangjing Lu, H. Yin, Jieying Wang, 2023, Frontiers in Medicine.

Duration biased distribution of clinical and immunological phenotypes in active SLE

Liangjing Lu, Jieying Wang, Q. Yan, 2022, Frontiers in Immunology.

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study

C. Bao, Fang Du, M. Dai, 2023, Frontiers in Immunology.

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al

H. Yin, Q. Yan, L. Lu, 2022, Arthritis & rheumatology.

Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis

O. Distler, Liangjing Lu, Xueyu Dai, 2023, Arthritis & rheumatology.

Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma

Liangjing Lu, Shaoying Yang, H. Yin, 2022, Clinical and experimental dermatology.